Posted on

HAVN Life Enters Supply Agreement With MPB Group Inc.

HAVN Life Enters Supply Agreement With MPB Group Inc.

This new partnership will see the distribution of the Company’s standardized, naturally derived, psilocybin containing mushrooms for therapeutic use at Healing Escapes Foundation retreats in Jamaica

Vancouver, BC – Havn Life Sciences Inc. (CSE: HAVN) (OTC: HAVLF) (FSE: 5NP) (the “Company” or “HAVN Life”) a biotechnology company pursuing standardized extraction of psychoactive compounds and the development of natural health products, is pleased to announce it has entered into a supply partnership with MPB Group Inc. (the “Supply Agreement”), a comprehensive outpatient mental health clinic with locations in Columbia and Laurel, Maryland that is helping adults, children, adolescents, couples, and families navigate the path to healing. MPB Group Inc. is partnered with Healing Escapes Foundation retreats, a non-profit organization focused on creating immersive, holistic mental health retreats for couples and adults in Jamaica.

HAVN Life will supply naturally derived psilocybin for use during Healing Escapes Foundation retreat programs, which operate in compliance with local and international protocols. The Supply Agreement will provide MPB Group Inc. with product from HAVN Life’s facility in Jamaica, where mushrooms are cultivated under GACP and processed in a GMP facility, ensuring greater consistency and more accurate dosing, as well as higher bioavailability compared to alternative local sources.

“We are thrilled to enter into a partnership with MPB Group Inc.,” says HAVN Life CEO Tim Moore. “For the past year, our Research and Development team has been working diligently in Jamaica, laying the foundation for our global supply of psilocybin mushrooms and related products. Because of the standardized, high quality of our naturally derived psilocybin, we are now attracting partners like MPB Group Inc., who are operating within the therapeutic retreat space and are happy to be able to meet this demand,” he adds.

“Together with the Healing Escapes Foundation, MPB Group Inc. is very excited about this collaboration with HAVN Life, due to the quality of their naturally derived psilocybin which will be offered at our psychedelic-assisted retreats – facilitated by licensed mental health clinicians in pristine Jamaica,” says Mika Uematsu, LCSW-C, Director of Trauma Recovery Program and Chief Psychedelic Officer.

Havn Life’s operations in Jamaica are facilitated by strategic partnerships with Hypha Wellness and P.A. Benjamin Manufacturing Company to provide cultivation and processing facilities for psilocybin containing mushrooms, solidifying relationships with local partners.

###
On Behalf of The Board of Directors
Tim Moore
Chief Executive Officer

About HAVN Life Sciences Inc.
HAVN Life Sciences is a biotechnology company pursuing standardized extraction of psychedelic compounds for the creation of APIs, the development of natural health products, and innovative therapies to support brain health and enhance the capabilities of the mind.

Through its research division, HAVN Labs, the company has developed an end-to-end supply chain of GMP naturally derived psychedelic compounds for research that will define the future of modern medicine. With its new line of natural health products, HAVN Life offers a full range of high-quality mushroom and plant extracts that help boost immune function, reduce inflammation and support a healthy lifestyle.

Purchase our products and find out more at yourhavnlife.com, and follow us on Facebook, Twitter, Instagram and Youtube.

About MPB Group Inc.
Founded in 2003, MPB Group Inc. is a comprehensive outpatient mental health clinic with a mission to provide comprehensive, accessible and culturally competent mental health services to adults, children, adolescents, couples, and families to heal from dysfunctional patterns of behaviour. MPB Group Inc. is partnered with Healing Escapes Foundation retreats in Jamaica – luxury, holistic mental health retreats that tap into the five senses to help escape, surrender and restore balance. For more information, please visit www.mpbhealth.com.

Contact:
Investor Relations: ir@havnlife.com
Media: savi@emergence-creative.com

Forward-Looking Information: This news release contains “forward-looking information” within the meaning of applicable securities laws relating to statements regarding the Supply Agreement, the Company’s business, products and future of the Company’s business. Although the Company believes that the expectations reflected in the forward-looking information are reasonable, there can be no assurance that such expectations will prove to be correct. Readers are cautioned not to place undue reliance on forward-looking information. Such forward-looking statements are subject to risks and uncertainties that may cause actual results, performance and developments to differ materially from those contemplated by these statements depending on, among other things, the risk that the supply of product pursuant to the Supply Agreement will not be completed as contemplated, or at all, risk that the anticipated benefits from the Supply Agreement will not be realized as contemplated, or at all, risks that the Company’s products and plan will vary from those stated in this news release and the Company may not be able to carry out its business plans as expected. Except as required by law, the Company expressly disclaims any obligation and does not intend to update any forward-looking statements or forward-looking information in this news release. Although the Company believes that the expectations reflected in the forward-looking information are reasonable, there can be no assurance that such expectations will prove to be correct. The statements in this news release are made as of the date of this release.

The CSE has not reviewed, approved or disapproved the content of this press release.

Posted on

HAVN Life to Be Featured on Viewpoint With Dennis Quaid

HAVN Life to Be Featured on Viewpoint With Dennis Quaid

The Company’s segment will be aired on public television networks across the U.S. starting in July, with interviews featuring CEO Tim Moore and the team leading HAVN Life’s Research and Development

Vancouver, BC – Havn Life Sciences Inc. (CSE: HAVN) (OTC: HAVLF) (FSE: 5NP) (the “Company” or “HAVN Life”) a biotechnology company pursuing standardized extraction of psychoactive compounds and the development of natural health products, is pleased to announce it will be featured in an upcoming Viewpoint with Dennis Quaid episode, airing in July. The episode of Viewpoint with Dennis Quaid will be distributed to more than 170 public television stations throughout the United States, reaching 60 million households throughout the year.

The segment includes an in-depth interview with HAVN Life CEO, Tim Moore, as well as clips from Chief Psychedelic Officer, Dr. Ivan Casselman, and Chief Research Officer, Alexzander Samuelsson, where they discuss the Company’s end-to-end research, extraction, formulation, and delivery of naturally derived psilocybin, and some of the strategic, research and supply partnerships HAVN Life has secured. They also touch on HAVN Life’s commitment to advancing psychedelic medicine through clinical research and therapeutic use as a ground-breaking medicine with the potential to provide better mental and cognitive health solutions at a global scale.

“We’re absolutely thrilled to be a part of the Viewpoint Project and in the illustrious company of previous guests including former U.S. Secretary of State, Colin Powell, Governor of Iowa Kim Reynolds and the 41st President of the United States, George H.W. Bush, among others,” says HAVN Life CEO, Tim Moore. “The format of the program provides a unique educational platform for the most talked about issues of the day, and we truly feel that psychedelics deserve such a platform. We are proud to be a part of the movement that is helping to redefine and rehabilitate psychedelics in the popular imagination,” he adds.

“From the very start, our mission has been to bring medicine to the people,” says HAVN Life Chief Psychedelic Officer, Dr. Ivan Casselman. “I am excited to see all the global momentum in psychedelic medicine – the future is bright,” he adds.

“As part of the evolving psychedelic industry, I’m proud of the way HAVN Life has been able to take a leading role in sharing information and perspectives on the history of psychedelics, its usage, and the huge potential that psilocybin-based therapies have to offer,” says Alexzander Samuelsson, Chief Research Officer at HAVN Life. “Through our work and partnerships, we are building a pathway to healing and relief for those suffering from mental health issues, which many people have been dealing with during the past two years of pandemic lockdowns, isolation, opportunity and personal losses,” he adds.

The HAVN Life segment on Viewpoint with Dennis Quaid will make its debut on public television in July. Additionally, a recently produced network-quality commercial featuring HAVN Life’s natural health products will debut twice during prime time on Fox Business in July. The commercials will continue to air up to 400 times during the year, reaching 84 million homes on networks such as CNBC, CNN Headline News, The Learning Channel, Discovery and Discovery Life, among others.

The Company also announces that on May 26, 2022, it granted 3,000,000 stock options to Tim Moore and 1,000,000 stock options to Gordon Clissold. The stock options are exercisable for a period of five (5) years at a price of $0.06 per common share.

###
On Behalf of The Board of Directors
Tim Moore
Chief Executive Officer

About HAVN Life Sciences Inc.
HAVN Life Sciences is a biotechnology company pursuing standardized extraction of psychedelic compounds for the creation of APIs, the development of natural health products, and innovative therapies to support brain health and enhance the capabilities of the mind.

Through its research division, HAVN Labs, the company has developed an end-to-end supply chain of GMP naturally derived psychedelic compounds for research that will define the future of modern medicine. With its new line of natural health products, HAVN Life offers a full range of high-quality mushroom and plant extracts that help boost immune function, reduce inflammation and support a healthy lifestyle.

Purchase our products and find out more at yourhavnlife.com, and follow us on Facebook, Twitter, Instagram and Youtube.

About the Viewpoint Project
The goal of the Viewpoint Project is to enlighten the audience by delivering diverse informational and educational documentaries by covering a variety of issues and topics. Viewpoint Project is on the cutting edge of the television documentary industry, producing top quality programming for Public Television. Viewpoint Project is dedicated to the mission of developing and distributing social and educational programming about our neighbors, our community, and world. Each story has one thing in common – changing our lives for the better.

Contact:
Investor Relations: ir@havnlife.com
Media: savi@emergence-creative.com

Forward-Looking Information: This news release contains “forward-looking information” within the meaning of applicable securities laws relating to statements regarding the Company’s feature on Viewpoint with Dennis Quaid, the Company’s work to build a pathway to healing and relief for those suffering from mental health issues, the Company’s business, products and future of the Company’s business. Although the Company believes that the expectations reflected in the forward-looking information are reasonable, there can be no assurance that such expectations will prove to be correct. Readers are cautioned not to place undue reliance on forward-looking information. Such forward-looking statements are subject to risks and uncertainties that may cause actual results, performance and developments to differ materially from those contemplated by these statements depending on, among other things, the risk that the Company’s feature on Viewpoint with Dennis Quaid will not be completed as contemplated, or at all, risks that the Company’s work to build a pathway to healing and relief for those suffering from mental health issues will not be completed as contemplated, or at all, risks that the Company’s products and plan will vary from those stated in this news release and the Company may not be able to carry out its business plans as expected. Except as required by law, the Company expressly disclaims any obligation and does not intend to update any forward-looking statements or forward-looking information in this news release. Although the Company believes that the expectations reflected in the forward-looking information are reasonable, there can be no assurance that such expectations will prove to be correct. The statements in this news release are made as of the date of this release.

The CSE has not reviewed, approved or disapproved the content of this press release.

Posted on

HAVN Life Announces Changes to the Board of Directors

HAVN Life Announces Changes to the Board of Directors

Vancouver, BC – Havn Life Sciences Inc. (CSE: HAVN) (OTC: HAVLF) (FSE: 5NP) (the “Company” or “HAVN Life”) announces the departure of Messrs. Victor Neufeld and Dennis Staudt, respectively, as Directors of the Company (“Board”), effective immediately. The Company expresses its appreciation for Mr. Neufeld and Mr. Staudt’s services to the Company and wishes them the very best.

Stated Mr. Neufeld, “Both Dennis and myself have enjoyed our tenure on the Board, assisting and mentoring the HAVN strategic vision as the Company pursued opportunities in the psychedelic and functional mushroom sectors. Our Board resignations reflect other personal commitments, but we remain supportive long term shareholders.”

The Company is pleased to announce that Mr. Tim Moore, Chief Executive Officer and Director, has been appointed Chairman of the Board, and that Mr. Gordon Clissold, the Company’s Chief Financial Officer, has been appointed as a Director.

On Behalf of The Board of Directors
Tim Moore
CEO

About HAVN Life Sciences Inc.
HAVN Life Sciences Inc. is a Canadian biotechnology company pursuing standardized extraction of psychoactive compounds, the development of natural healthcare products, and innovative mental health treatment to support brain health and enhance the capabilities of the mind. Learn more at: havnlife.com and follow us on Facebook, Twitter and Instagram.

Contact:
Investor Relations: ir@havnlife.com 604 359 0060
Media: savi@emergence-creative.com 647 896-8078

The CSE has not reviewed, approved or disapproved the content of this press release

Posted on

HAVN Life Announces Strategic Partnership With Non-profit Coalition, TheraPsil

HAVN Life Announces Strategic Partnership With Non-profit Coalition, TheraPsil

Through the Partnership, the Company will seek Health Canada approval to supply naturally-derived psilocybin for legal and therapeutic use via the Special Access Program

Vancouver, BC – Havn Life Sciences Inc. (CSE: HAVN) (OTC: HAVLF) (FSE: 5NP) (the “Company” or “HAVN Life”), a biotechnology company pursuing standardized extraction of psychoactive compounds and the development of natural health products, is pleased to announce a partnership (the “Partnership”) with TheraPsil – a non-profit coalition made up of healthcare professionals, patients, community members, and advocates dedicated to helping Canadians in medical need access legal psilocybin-assisted psychotherapy and GMP-quality psilocybin. Under the Partnership, TheraPsil will support prescribing healthcare professionals in requesting psilocybin from HAVN Life, and other licensed dealers enrolled in TheraPsil’s “Project Solace”, through the Special Access Program (“SAP”).

Health Canada has designated the Special Access Program, along with clinical trials, as a preferred pathway for patients to access psilocybin for medical purposes. Under SAP, prescribing healthcare professionals can request psilocybin manufactured by Health Canada-approved licensed dealers for seriously-ill patients requiring emergency access to this medicine.

Through this Partnership, HAVN Life will participate in TheraPsil’s Project Solace – an effort to secure a safe supply of psilocybin for patients in medical need while developing a substantial body of evidence using a real-world data registry to document clinical effectiveness, safety, and clinician and patient reported outcomes in those who have received medical psilocybin-assisted psychotherapy via SAP. The data will then be provided to ‎stakeholders, policy makers, and regulatory bodies to facilitate decision-making around the regulatory ‎system for the future of medicalized psilocybin.

“The goal of HAVN Life, since its inception, has been to support and serve communities in need of cognitive and mental health treatment alternatives,“ says HAVN Life CEO, Tim Moore. “We feel well aligned with organizations like TheraPsil, who are advocating for compassionate access to psilocybin-assisted psychotherapy for Canadians in medical need, as well as making strides in creating a framework for what medicalized psilocybin may look like in the near future. We are thrilled to participate in Project Solace, which aims to move the needle on regulatory guidelines in Canada,” he adds.

Patient rights advocate and TheraPsil CEO, Spencer Hawkswell had this to say: “Thousands of Canadians are in urgent need of psilocybin for medical purposes. Our goal with Project Solace is to make access easier for patients through Health Canada’s preferred pathway, the SAP. With the support of HAVN Life, a founding member of Project Solace, patients in medical need will get streamlined access, a safe supply of psilocybin, and support from therapy teams to facilitate their treatment. Data collected through this project will help inform regulatory improvements, and move Canada closer to legalizing psilocybin for medical purposes.”

Data collected from Project Solace will be a critical tool for prescribing healthcare professionals, and help future patients decide which licensed dealers’ psilocybin products best suit their medical needs. The data will also be released to licensed dealers enrolled in the RWD program and the general public.

HAVN Life’s operations in Jamaica are facilitated by strategic partnerships with Hypha Wellness and P.A. Benjamin Manufacturing Company to provide cultivation and processing facilities for psilocybin containing mushrooms, solidifying relationships with local partners.

###
On Behalf of The Board of Directors
Tim Moore
Chief Executive Officer

About HAVN Life Sciences Inc.
HAVN Life Sciences is a biotechnology company pursuing standardized extraction of psychedelic compounds for the creation of APIs, the development of natural health products, and innovative therapies to support brain health and enhance the capabilities of the mind.

Through its research division, HAVN Labs, the company has developed an end-to-end supply chain of standardized, naturally derived psychedelic compounds for research that could define the future of modern medicine. With its new line of natural health products, HAVN Life Retail offers a full range of high-quality mushroom and plant extracts that help boost immune function, reduce inflammation and support a healthy lifestyle.

Purchase our products and find out more at yourhavnlife.com, and follow us on Facebook, Twitter, Instagram and Youtube.

About TheraPsil
TheraPsil is a non-profit coalition of healthcare professionals, patients, and advocates dedicated to obtaining access to safe, effective, and legal psilocybin-assisted psychotherapy for Canadians experiencing end-of-life distress.

Contact:
Investor Relations: ir@havnlife.com 604 687-7130
Media: savi@emergence-creative.com 647 896-8078

Forward-Looking Information: This news release contains “forward-looking information” within the meaning of applicable securities laws relating to statements regarding the Partnership, the Company’s business, products and future of the Company’s business. Although the Company believes that the expectations reflected in the forward-looking information are reasonable, there can be no assurance that such expectations will prove to be correct. Readers are cautioned not to place undue reliance on forward-looking information. Such forward-looking statements are subject to risks and uncertainties that may cause actual results, performance and developments to differ materially from those contemplated by these statements depending on, among other things, the risk that the anticipated benefits of the Partnership will be realized as contemplated, or at all, risks that the Company’s products and plan will vary from those stated in this news release and the Company may not be able to carry out its business plans as expected. Except as required by law, the Company expressly disclaims any obligation and does not intend to update any forward-looking statements or forward-looking information in this news release. Although the Company believes that the expectations reflected in the forward-looking information are reasonable, there can be no assurance that such expectations will prove to be correct. The statements in this news release are made as of the date of this release.

The CSE has not reviewed, approved or disapproved the content of this press release

Posted on

HAVN Life Ships First White Label Order to Distribution Partner Woke Pharmaceuticals in Australia

HAVN Life Ships First White Label Order to Distribution Partner Woke Pharmaceuticals in Australia

The successful shipment of white label natural health products will expand the Company’s global retail footprint

Vancouver, BC – Havn Life Sciences Inc. (CSE: HAVN) (OTC: HAVLF) (FSE: 5NP) (the “Company” or “HAVN Life”) a biotechnology company pursuing standardized extraction of psychoactive compounds and the development of natural health products, is pleased to announce it has successfully shipped its first order of white label natural health products to their Australian distribution partner, Woke Pharmaceuticals Pty Ltd. (“Woke Pharmaceuticals”).

The distribution agreement, signed between the two companies in November 2021, will see the white label products available through Australian retailers, including major supermarkets and other retail outlets, as well as through various e-commerce portals such as Australia and New Zealand Amazon sites.

“We are very pleased to make this first shipment of HAVN white label products into what we anticipate will be a very strong market,” says HAVN Life CEO, Tim Moore. “With this shipment and our recent launch of the Brain Evolve Series in North America, we’re making good on our promise of retail expansion, with more global distribution growth planned for the near future,” he adds.

The partnership between HAVN Life and Woke Pharmaceuticals will see their white label products brought to market in Australia, New Zealand and China, whose natural health product market is forecasted to reach US $52 billion in 2023.

###
On Behalf of The Board of Directors
Tim Moore
Chief Executive Officer

About HAVN Life Sciences Inc.
HAVN Life Sciences is a biotechnology company pursuing standardized extraction of psychedelic compounds for the creation of APIs, the development of natural health products, and innovative therapies to support brain health and enhance the capabilities of the mind.

Through its research division, HAVN Labs, the company has developed an end-to-end supply chain of GMP naturally derived psychedelic compounds for research that will define the future of modern medicine. With its new line of natural health products, HAVN Life offers a full range of high-quality mushroom and plant extracts that help boost immune function, reduce inflammation, and support a healthy lifestyle.

Purchase our products and find out more at yourhavnlife.com, and follow us on Facebook, Twitter, Instagram and Youtube.

About Woke Pharmaceuticals
Woke Pharmaceuticals Pty Ltd is an Australian-based company focused on the development and commercialisation of novel psychedelic therapies for the treatment of mental health disorders. The Company’s lead candidates are based on synthetic psilocybin for the treatment of depression. Woke Pharmaceuticals is developing a novel micro-dose formulation for treatment of moderate depression and a novel high-dose formulation with concomitant psychotherapy for treatment of major depression. Both candidates are expected to enter Phase II trials in 2022 with leading investigators in the field of mental health. For further information, please visit www.wokeph.com.

Contact:
Investor Relations: ir@havnlife.com
Media: savi@emergence-creative.com

Forward-Looking Information: This news release contains “forward-looking information” within the meaning of applicable securities laws relating to statements regarding the shipment of the white label products to Woke Pharmaceuticals under the distribution agreement (the “Shipment”), the Company’s business, products and future of the Company’s business. Although the Company believes that the expectations reflected in the forward-looking information are reasonable, there can be no assurance that such expectations will prove to be correct. Readers are cautioned not to place undue reliance on forward-looking information. Such forward-looking statements are subject to risks and uncertainties that may cause actual results, performance and developments to differ materially from those contemplated by these statements depending on, among other things, the risk that the Shipment will not be completed as contemplated, or at all, risks that the Company’s products and plan will vary from those stated in this news release and the Company may not be able to carry out its business plans as expected. Except as required by law, the Company expressly disclaims any obligation and does not intend to update any forward-looking statements or forward-looking information in this news release. Although the Company believes that the expectations reflected in the forward-looking information are reasonable, there can be no assurance that such expectations will prove to be correct. The statements in this news release are made as of the date of this release.

The CSE has not reviewed, approved or disapproved the content of this press release.

Posted on

HAVN Life Launches the Brain Evolve Series

HAVN Life Launches the Brain Evolve Series

The four formulations, helping to reduce inflammation, promote restorative sleep and support cognitive function are now available on yourhavnlife.com

Vancouver, BC – Havn Life Sciences Inc. (CSE: HAVN) (OTC: HAVLF) (FSE: 5NP) (the “Company” or “HAVN Life”), a biotechnology company developing natural health products and innovative therapies to support brain health and cognitive function, is pleased to announce the launch of its second line of natural health products—the Brain Evolve Series. The four new SKUs— Brain Evolve AM, Brain Evolve PM Flavoured, Brain Evolve PM Unflavoured and Brain Evolve Anti-Aging—are now available for purchase on yourHAVNlife.com, shipping across Canada and the U.S. The full line will also be available on Amazon and at GNC locations across Canada in late spring.

HAVN Life’s Brain Evolve Series includes a range of natural ingredients that are known to support trauma recovery and counteract the effects of brain degeneration. Each formulation is designed to support inflammation reduction and restorative sleep, and promote increased energy and memory.

Created and patented by HAVN Life’s Director of Education, Matthew Bennett, the Brain Evolve Series formulations were designed to address symptoms of concussion and traumatic brain injury, as well as support cognitive health. As an athletic therapist with expertise in concussion management, Mr. Bennett understood that the symptoms of concussion and trauma—poor sleep, fatigue and lack of clarity—are caused primarily by inflammation. With his goal to reduce inflammation in the brain and body for his clients, Bennett was able to find success in addressing symptoms of concussion and traumatic brain injury, inspiring his journey into the nutraceutical industry.

Throughout his career as an athletic therapist, Matthew Bennett has helped various sports professionals to recover from trauma and brain injuries and the success of his programs led him to design the Brain Evolve Series – meant for anyone looking to support, recover and protect their cognitive health. The Brain Evolve formulations have been used by performance nutritionists and individual players across the NHL®, NFL®, NBA® and AHL® as part of their player brain health recovery regimens.

The Future of Brain Health Support and Trauma Recovery
The effects of trauma can last for several days, weeks, or months, taking a toll on day-to-day living and activities. Symptoms can range from headache, dizziness, brain fog and nausea to disruption in eating, sleeping and elimination habits. Scientific research has shown that there is currently limited effective pharmaceutical treatment for traumatic injury, and has pointed to a larger picture of what occurs in the body following brain injury—most notably the changes in nutrient levels within the brain and body.

The Brain Evolve Series is formulated with natural ingredients that are known to support recovery, help cognitive function and promote restorative sleep:

  • Brain Evolve AM: This patented blend of antioxidants supports cognitive health maintenance and brain function, while giving you more energy and greater focus during the day. (CAD $89.99 + tax )
  • Brain Evolve PM (Flavoured and Unflavoured): These formulations contain 16 natural ingredients, including amino acids, Melatonin, and Curcumin, known to work synergistically to:
    • Reduce inflammation
    • Increase energy and flow of nutrients to the brain to encourage healing
    • Regulate hormones that contribute to restorative sleep so the body can heal
    • Meant to be taken before bed, the flavoured formulation features the refreshing taste of tropical fruit. (CAD $89.99 + tax)
  • Brain Evolve Anti-Aging: This formulation assists with issues related to brain aging,like neurodegeneration and cognitive impairment, using key ingredients :
    • Curcumin: reduces inflammation
    • Melatonin: helps with sleep
    • Astaxanthin: known to reduce eye inflammation
    • Creatine: ergogenic agent for recovery after activity (CAD $89.99+ tax)

“With the launch of the Brain Evolve Series, HAVN Life demonstrates its commitment to helping communities thrive, bringing high-quality and science-based nutraceuticals to market over the past 12 months,” says Tim Moore, CEO of HAVN Life. “With multiple distribution and supply partnerships in place in Canada, the U.S. and Australia, our goal is to consolidate our retail presence globally, as a go-to purveyor of the best available products that support brain health and cognitive function. We are very excited about the healing potential of this new product line,” he adds.

“I’m very excited to launch the Brain Evolve series with HAVN Life,” says HAVN Life Director of Education, Matthew Bennett. “My goal in creating these formulations was to support people with concerns around sleep, brain injury, brain wellness and prevention of neurodegeneration, as well as anyone looking to optimize their overall cognitive health. By joining the HAVN Life team, I’m happy to see the products I created reach a wider audience, helping families and communities to thrive,” he adds.

In addition to the Brain Evolve Series, HAVN Life launched a full line of vegan and non-GMO natural health products in June 2021. Thoughtfully formulated with adaptogens and antioxidants to support brain health, these natural compounds are proven to support memory, focus, energy, and overall cognitive function. The product line includes Rhodiola Relief, Mind Mushroom, Chaga Immunity, Reishi Recharge, Bacopa Brain, Lion’s Mane and Cordyceps Perform and is available through yourhavnlife, Amazon and at select natural health store locations across Alberta and British Columbia.

*Supporting Research Studies are available HERE

###
On Behalf of The Board of Directors
Tim Moore
Chief Executive Officer

About HAVN Life Sciences Inc.
HAVN Life Sciences is a biotechnology company pursuing standardized extraction of psychedelic compounds for the creation of active pharmaceutical ingredients (“API”), the development of natural health products, and innovative therapies to support brain health and cognitive function.

Through its research division, HAVN Labs, the company has developed an end-to-end supply chain of GMP naturally derived psychedelic compounds for research that will define the future of modern medicine. With its new line of natural health products, HAVN Life offers a full range of high-quality mushroom and plant extracts that help boost immune function, reduce inflammation and support a healthy lifestyle.

Purchase our products and find out more at yourhavnlife.com, and follow us on Facebook, Twitter, Instagram and Youtube.

The natural health product licenses for products Brain Evolve AM, Brain Evolve PM Flavoured, Brain Evolve PM Unflavoured and Brain Evolve Anti-Aging are currently registered to Bennett’s Choice, a company owned by HAVN Life Retail.

Contact:
Investor Relations: ir@havnlife.com
Media: savi@emergence-creative.com

Forward-Looking Information: This news release contains “forward-looking information” within the meaning of applicable securities laws relating to statements regarding the Company’s business, products and future of the Company’s business, including the introduction of the Brain Evolve Series to the Company’s natural health product line. Although the Company believes that the expectations reflected in the forward-looking information are reasonable, there can be no assurance that such expectations will prove to be correct. Readers are cautioned not to place undue reliance on forward-looking information. Such forward-looking statements are subject to risks and uncertainties that may cause actual results, performance and developments to differ materially from those contemplated by these statements depending on, among other things, the risks that the anticipated benefits of the introduction of the Brains Evolve Series to the Company’s natural health product line will not be realized as contemplated, or at all , and risks that the Company’s products and plan will vary from those stated in this news release and the Company may not be able to carry out its business plans as expected. Except as required by law, the Company expressly disclaims any obligation and does not intend to update any forward-looking statements or forward-looking information in this news release. Although the Company believes that the expectations reflected in the forward-looking information are reasonable, there can be no assurance that such expectations will prove to be correct. The statements in this news release are made as of the date of this
release.

The CSE has not reviewed, approved or disapproved the content of this press release

Posted on

HAVN Life Closes C$2,000,000 Private Placement With U.S. Institutional Investors

HAVN Life Closes C$2,000,000 Private Placement With U.S. Institutional Investors

Vancouver, BC – Havn Life Sciences Inc. (CSE: HAVN) (OTC: HAVLF) (FSE: 5NP) (the “Company” or “HAVN Life”), a biotechnology company developing natural health products and innovative therapies to support brain health and cognitive function, is pleased to announce that it has closed its previously announced sale of units to U.S. institutional investors, for gross proceeds of approximately C$2,000,000, on a private placement basis in the United States (the “Private Placement”).

Pursuant to the Private Placement, the Company issued 20,537,126 units (the “Units”) at a price of C$0.087 per Unit and 2,451,380 pre-funded units (the “Pre-Funded Units”) at a price of C$0.0869 per Pre-Funded Unit. Each Unit is comprised of one common share of the Company (a “Common Share”) and one Common Share purchase warrant (a “Warrant”). Each Warrant entitles the holder to purchase one Common Share (a “Warrant Share”) at an exercise price of C$0.125 per Warrant Share, subject to adjustment, at any time on or prior to 5:00 p.m. (Eastern Standard Time) on March 3, 2027. Each Pre-Funded Unit is comprised of one pre-funded Common Share purchase warrant (a “Pre-Funded Warrant”) and one Warrant. Each Pre-Funded Warrant entitles the holder thereof to purchase one Common Share (a “Pre-Funded Warrant Share”) at an exercise price of C$0.0001 per Pre-Funded Warrant Share and shall terminate upon exercise in full of the Pre-Funded Warrants.

H.C. Wainwright & Co. (“H.C. Wainwright”) acted as the exclusive placement agent for the Private Placement.

H.C. Wainwright received (i) a cash commission of $160,000 (equal to 8% of the gross proceeds of the Private Placement) and (ii) 1,839,080 compensation warrants (the “Agent Warrants”). Each Agent Warrant entitles the holder thereof to purchase one Common Share at an exercise price of C$0.125 per Common Share at any time on or prior to 5:00 pm (Eastern Standard Time) on March 3, 2027.

The Common Shares, Pre-Funded Warrants and Warrants issued under the Private Placement were qualified by way of a prospectus supplement dated March 2, 2022 under the Company’s short form base shelf prospectus dated October 4, 2021 (the “Prospectus Supplement”) which was filed in the Province of British Columbia. In the United States, the Common Shares, Warrants, Pre-Funded Warrants, Warrant Shares issuable upon exercise of the Warrants and the Pre-Funded Warrant Shares issuable upon exercise of the Pre-Funded Warrants were offered on a private placement basis pursuant to exemptions from the registration requirements of the United States Securities Act of 1933, as amended (the “U.S. Securities Act”).

The Company intends to use the net proceeds of the Private Placement for general working capital purposes. The Private Placement is subject to customary notices and deliveries to the Canadian Securities Exchange.

This news release shall not constitute an offer to sell or a solicitation of an offer to buy nor shall there be any sale of any of the securities in any jurisdiction in Canada in connection with the Private Placement.

This news release shall not constitute an offer to sell or the solicitation of an offer to buy any securities, nor shall there be any sale of the securities in any jurisdiction in which such offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of any such jurisdiction. The securities referred in this news release have not been, nor will they be, registered under the United States Securities Act of 1933, as amended, (the “U.S. Securities Act”), or any U.S. state securities laws, and such securities may not be offered or sold within the United States or to any U.S. person absent registration under U.S. federal and state securities laws or an applicable exemption from such U.S. registration requirements. “United States” and “U.S. person” have the respective meanings ascribed to them in Regulation S under the U.S. Securities Act.

###
On Behalf of The Board of Directors
Tim Moore
Chief Executive Officer

About HAVN Life Sciences Inc.
HAVN Life Sciences is a biotechnology company pursuing standardized extraction of psychedelic compounds for the creation of APIs, the development of natural health products, and innovative therapies to support brain health and cognitive function.

Through its research division, HAVN Labs, the company has developed an end-to-end supply chain of standardized, naturally derived psychedelic compounds for research that will define the future of modern medicine. With its new line of natural health products, HAVN Life offers a full range of high-quality mushroom and plant extracts that help boost immune function, reduce inflammation and support a healthy lifestyle.

Purchase our products and find out more at yourhavnlife.com, and follow us on Facebook, Twitter, Instagram and Youtube.

Contact:
Investor Relations: ir@havnlife.com 604 687-7130
Media: savi@emergence-creative.com 647 896-8078

Forward-Looking Information: This news release contains “forward-looking information” within the meaning of applicable Canadian securities laws and may also contain statements that may constitute “forward-looking statements” within the meaning of the safe harbor provisions of the United States Private Securities Litigation Reform Act of 1995. The “forward-looking information” herein may include, but is not limited to, the use of the net proceeds of the Private Placement and the receipt of all necessary regulatory and stock exchange approvals for the Private Placement.

Although the Company believes that the expectations reflected in the forward-looking information are reasonable, there can be no assurance that such expectations will prove to be correct. Readers are cautioned not to place undue reliance on forward-looking information. Such forward-looking statements are subject to risks and uncertainties that may cause actual results, performance and developments to differ materially from those contemplated by these statements depending on, among other things, the risks and uncertainties relating to direct and indirect material adverse effects from the COVID-19 pandemic; inability to obtain future financing on suitable terms; failure to obtain required regulatory and other approvals; risks inherent in the biotechnology sector; changes in applicable laws and regulations; and failure to comply with applicable laws and regulations.

Except as required by law, the Company expressly disclaims any obligation and does not intend to update any forward-looking statements or forward-looking information in this news release. Although the Company believes that the expectations reflected in the forward-looking information are reasonable, there can be no assurance that such expectations will prove to be correct. The statements in this news release are made as of the date of this release.

The CSE has not reviewed, approved or disapproved the content of this press release

Posted on

HAVN Life Announces Distribution Deal With Jonluca Enterprises Inc.

HAVN Life Announces Distribution Deal With Jonluca Enterprises Inc.

With this deal, The Company’s full line of natural health formulations will now be available across Canada at select health food store locations

Vancouver, BC – Havn Life Sciences Inc. (CSE: HAVN) (OTC: HAVLF) (FSE: 5NP) (the “Company” or “HAVN Life”) a biotechnology company pursuing standardized extraction of psychoactive compounds and the development of natural health products, is pleased to announce it has secured a distribution deal with Jonluca Enterprises Inc. for the company’s line of natural health products, launched in June of last year. The deal will enable HAVN Life products to be distributed nationally through purveyors of natural and organic products.
“We are absolutely thrilled at this opportunity to see our formulations on shelves from coast to coast,” says HAVN Life CEO Tim Moore. “We are excited to connect with communities across the country and help them build and empower their health and wellbeing, while growing our own footprint in the natural health space,” he adds.

“We’re very excited to work with HAVN Life, listing them nationally,” says Casey Eleusiniotis, President of Jonluca Enterprises Inc. “We strive to get healthy life options to more Canadians, and we’re aligned beautifully with HAVN in that effort. We’re looking forward to working together and offering something positive to the industry,” he adds.

Securing this distribution deal with Jonluca underpins the expansion of HAVN Life’s retail and distribution network , which now includes Calgary Co-op locations in Alberta, Choices Market and Nesters Market locations in B.C., as well as online retailers Well.ca and Amazon.ca and Amazon.com, and through their own ecommerce site, yourhavnlife.com, shipping across North America and internationally.

HAVN Life formulations are non-GMO, vegan, bioavailable, naturally-derived from functional mushrooms and other plants and created with human optimization in mind.
The natural health product line has been thoughtfully formulated with adaptogens and antioxidants to support overall brain health, with natural compounds that are proven to support memory, focus, energy, and overall cognitive function.

###
On Behalf of The Board of Directors
Tim Moore
Chief Executive Officer

About HAVN Life Sciences Inc.
HAVN Life Sciences is a biotechnology company pursuing standardized extraction of psychedelic compounds for the creation of APIs, the development of natural health products, and innovative therapies to support brain health and enhance the capabilities of the mind.

Through its research division, HAVN Labs, the company has developed an end-to-end supply chain of GMP naturally derived psychedelic compounds for research that will define the future of modern medicine. With its new line of natural health products, HAVN Life offers a full range of high-quality mushroom and plant extracts that help boost immune function, reduce inflammation and support a healthy lifestyle.

Purchase our products and find out more at yourhavnlife.com, and follow us on Facebook, Twitter, Instagram and Youtube.

About Jonluca Enterprises Inc.
Jonluca Enterprises was founded in 2010, by two brothers and a single van. We saw that there was a demand for a distributor that understands the needs of the natural and organic industry. With this goal in mind Casey and Yian started delivering ice cream and Jonluca was born. By staying true to our core value and partnering with brands that align with our values, we can provide excellent service, and as a result we have grown into a full-service National distributor. Over time, we have developed our core strengths by promoting local partnerships, building lasting relationships, supporting sustainable and local products, and traceability in consumables.

Contact:
Investor Relations: ir@havnlife.com 604 687-7130
Media: savi@emergence-creative.com 647 896-8078

Forward-Looking Information: This news release contains “forward-looking information” within the meaning of applicable securities laws relating to statements regarding the Acquisition, the Company’s business, products and future of the Company’s business. Although the Company believes that the expectations reflected in the forward-looking information are reasonable, there can be no assurance that such expectations will prove to be correct. Readers are cautioned not to place undue reliance on forward-looking information. Such forward-looking statements are subject to risks and uncertainties that may cause actual results, performance and developments to differ materially from those contemplated by these statements depending on, among other things, the risk that the Acquisition will not be completed as contemplated, or at all, risks that the Company’s products and plan will vary from those stated in this news release and the Company may not be able to carry out its business plans as expected. Except as required by law, the Company expressly disclaims any obligation and does not intend to update any forward-looking statements or forward-looking information in this news release. Although the Company believes that the expectations reflected in the forward-looking information are reasonable, there can be no assurance that such expectations will prove to be correct. The statements in this news release are made as of the date of this release.

The CSE has not reviewed, approved or disapproved the content of this press release.

Posted on

HAVN Life to Present at Upcoming Emerging Growth Conference 26

HAVN Life to Present at Upcoming Emerging Growth Conference 26

CEO Tim Moore will share recent partnership and distribution news and a roadmap for the Company’s plans for the next quarter

Vancouver, BC – Havn Life Sciences Inc. (CSE: HAVN) (OTC: HAVLF) (FSE: 5NP) (the “Company” or “HAVN Life”), a biotechnology company pursuing standardized extraction of psychedelic compounds for the creation of APIs that support brain health and cognitive function, is announcing that CEO Tim Moore will be presenting at the Emerging Growth Conference, taking place on March 2nd , 2022.

HAVN Life CEO Tim Moore will give a presentation on March 2nd at 2pm (EST) sharing updates on the Company’s growth and activities to the investor audience. Mr. Moore will also host a Q & A session for investors following his presentation.

“I’m excited to once again be participating at the Emerging Growth Conference, and look forward to sharing our recent distribution and partnership successes, as well as upcoming plans with this illustrious group of investors and other emerging companies,” says Moore. “It’s a great opportunity to educate the investor community about the market potential of the work we’re doing,” he adds.

WHO: Tim Moore, CEO of HAVN Life Sciences Inc.
WHEN: Wednesday, March 2, 2022 at 2PM EST/ 11AM PST
WHERE: To register, please use the following link

If attendees are not able to attend on the day of the conference, an archived webcast will also be made available on EmergingGrowth.com post-event.

###
On Behalf of The Board of Directors
Tim Moore
Chief Executive Officer

About HAVN Life Sciences Inc.
HAVN Life Sciences is a biotechnology company pursuing standardized extraction of psychedelic compounds for the creation of APIs, the development of natural health products, and innovative therapies to support brain health and enhance the capabilities of the mind.

Through its research division, HAVN Labs, the company has developed an end-to-end supply chain of standardized, naturally derived psychedelic compounds for research that will define the future of modern medicine. With its new line of natural health products, HAVN Life offers a full range of high-quality mushroom and plant extracts that help boost immune function, reduce inflammation and support a healthy lifestyle.

Purchase our products and find out more at yourhavnlife.com, and follow us on Facebook, Twitter, Instagram and Youtube.

About the Emerging Growth Conference
The Emerging Growth Conference is an effective way for public companies to present and communicate their new products, services and other major announcements to the investment community from the convenience of their office, in a time efficient manner.

The Conference focus and coverage includes companies in a wide range of growth sectors, with strong management teams, innovative products & services, focused strategy, execution, and the overall potential for long term growth. Its audience includes potentially tens of thousands of Individual and Institutional investors, as well as Investment advisors and analysts.

All sessions will be conducted through video webcasts and will take place in the Eastern time zone.

Contact:
Investor Relations: ir@havnlife.com 604 687-7130
Media: savi@emergence-creative.com 647 896-8078

Forward-Looking Information: This news release contains “forward-looking information” within the meaning of applicable securities laws relating to statements regarding Mr. Moore’s attendance and presentation at the Virtual Investor Summit, the Company’s business, products and future of the Company’s business. Although the Company believes that the expectations reflected in the forward-looking information are reasonable, there can be no assurance that such expectations will prove to be correct. Readers are cautioned not to place undue reliance on forward-looking information. Such forward-looking statements are subject to risks and uncertainties that may cause actual results, performance and developments to differ materially from those contemplated by these statements depending on, among other things, the risk that Mr. Moore will not be able to attend and/or present at the Virtual Investor Summit as contemplated, or at all, risks that the Company’s products and plan will vary from those stated in this news release and the Company may not be able to carry out its business plans as expected. Except as required by law, the Company expressly disclaims any obligation and does not intend to update any forward-looking statements or forward-looking information in this news release. Although the Company believes that the expectations reflected in the forward-looking information are reasonable, there can be no assurance that such expectations will prove to be correct. The statements in this news release are made as of the date of this release.

The CSE has not reviewed, approved or disapproved the content of this press release

Posted on

HAVN Life Secures Purchase Order for Controlled Substance Sale to Revive Therapeutics Ltd. for Use in Clinical Research

HAVN Life Secures Purchase Order for Controlled Substance Sale to Revive Therapeutics Ltd. for Use in Clinical Research

The naturally derived GMP psilocybin will be exported through distribution partner Mycrodose Therapeutics Inc. to the University of Wisconsin-Madison, Contract Research Organization for Revive Therapeutics

VANCOUVER, BC, Feb. 24, 2022  – HAVN Life Sciences Inc. (CSE: HAVN) (OTC: HAVLF) (FSE: 5NP) (the “Company” or “HAVN Life”) a biotechnology company pursuing standardized extraction of psychedelic compounds for investigational research as potential APIs to support brain health and cognitive function, is pleased to announce it has successfully secured a purchase order for naturally derived psilocybin from their Canadian supply partner, Revive Therapeutics Ltd. (CSE: RVV) (OTC: RVVTF) (FSE: 31R) (“Revive”) for use in clinical research studies. The Company previously signed a supply agreement with Revive in October, 2021.

In fulfilling of the purchase order, HAVN Life will export naturally derived GMP psilocybin extract from its facility in Jamaica into the U.S. through its distribution partner, Mycrodose Therapeutics Inc. (“Mycrodose”) for use by the University of Wisconsin-Madison (“UW-Madison”), a Contract Research Organization (“CRO”) for Revive. This shipment of naturally derived psilocybin will allow UW-Madison to conduct research and formulation work to finalize dosing and delivery mechanisms in support of the various studies to be sponsored by Revive using an oral-thin and Hydra-gel delivery systems of psychedelics to treat mental health disorders.

“We are so pleased to be able to supply our naturally derived, GMP psilocybin for this potentially ground-breaking research related to addiction disorders,” says HAVN Life CEO Tim Moore. “It is our hope that research like this will help in the push toward the rescheduling of Schedule I compounds like psilocybin and psilocin, making treatment more accessible and helping to ease the growing mental health and addiction crisis we are facing today,” he adds.

“We are excited to work with HAVN Life to move forward with our investigational clinical trials including our project in Antigua“, says Revive CEO Michael Frank. He adds, “we are eager to advance the science on botanically-derived ingredients such as psilocin and psilocybin”.

“Mycrodose is very pleased to continue our efforts to progress the use of therapies based on botanically-derived psilocybin products with HAVN Life by expanding the use of psilocybin in research across the United States. Our DEA authorization to legally distribute psilocybin for authorized research purposes helps us facilitate the ease and access of using this Schedule I substance by DEA-licensed Universities, CROs, and other institutions in the United States,” says Chad Conner, Chief Executive Officer, Mycrodose Therapeutics. “We wish Revive Therapeutics and The University of Wisconsin-Madison continued success as they further progress their clinical trials investigation treatments,” he adds.

Revive Therapeutic Ltd. is a life sciences company focused on the research and development of therapeutics for rare disorders and infectious diseases. With its acquisition of Psilocin Pharma Corp. and advancements of its novel oral-thin film delivery system of psychedelic compounds, Revive is working to advance psilocybin-based therapeutics for mental health and abuse disorders.

Mycrodose is one of only a few US-pharmaceutical companies that has been authorized by the United States Drug Enforcement Agency (“DEA”), State of California Attorney General’s Research Advisory Board, and The Food & Drug Administration (“FDA”) to research and develop a total of eight (8) Schedule I and III compounds. In addition, the DEA has granted Mycrodose authorization to import and distribute for resale the controlled substances of psilocybin and psilocin to approved organizations for clinical trials, research and development, and analytical purposes.

HAVN Life’s operations in Jamaica are facilitated by strategic partnerships with Hypha Wellness and P.A. Benjamin Manufacturing Company to provide cultivation and processing facilities for psilocybe mushrooms.

On Behalf of The Board of Directors
Tim Moore
Chief Executive Officer

About HAVN Life Sciences Inc.

HAVN Life Sciences is a biotechnology company pursuing standardized extraction of psychedelic compounds for investigational research as potential APIs, the development of natural health products, and innovative therapies to support brain health and enhance the capabilities of the mind.

Through its research division, HAVN Labs, the company has developed an end-to-end supply chain of standardized, naturally derived psychedelic compounds for investigational research in an effort to define the future of modern medicine. HAVN Life offers a full range of high-quality mushroom and plant extracts that help support immune function and support a healthy lifestyle.

Purchase our plant-based Natural Health Products and find out more at yourhavnlife.com, and follow us on Facebook, Twitter,  Instagram and Youtube.

About Revive Therapeutics Ltd.

Revive Therapeutics Ltd. Therapeutics Ltd is a life sciences company focused on the research and development of therapeutics for infectious diseases and rare disorders, and it is prioritizing drug development efforts to take advantage of several regulatory incentives awarded by the FDA such as Orphan Drug, Fast Track, Breakthrough Therapy and Rare Pediatric Disease designations. Currently, the Company is exploring the use of Bucillamine for the potential treatment of infectious diseases, with an initial focus on severe influenza and COVID-19. With its acquisition of Psilocin Pharma Corp., Revive is advancing the development of Psilocybin-based therapeutics in various diseases and disorders. Revive’s cannabinoid pharmaceutical portfolio focuses on rare inflammatory diseases and the company was granted FDA orphan drug status designation for the use of Cannabidiol (CBD) to treat autoimmune hepatitis (liver disease) and to treat ischemia and reperfusion injury from organ transplantation.

About Mycrodose Therapeutics Inc.

Mycrodose Therapeutics Inc. is a U.S.-Based pharmaceutical company headquartered in San Diego, California specializing in the development of advanced drug delivery systems utilizing DEA Schedule I & III drugs and other compounds to treat cancer related conditions, mental health, and cognitive degenerative diseases. The company believes that its IP-Protected Sustained Microdosing Technology™ is a smarter and safer approach to delivering pharmaceutical compounds to patients of all ages and allows for an expandable and scalable business model.

Forward-Looking Information: This news release contains “forward-looking information” within the meaning of applicable securities laws relating to statements regarding the purchase order for naturally derived psilocybin from Revive (the “Purchase Order“), the exportation naturally derived GMP psilocybin extract from the Company’s facility in Jamaica into the U.S. through Mycrodose (the “Exportation“) and delivery of the naturally derived GMP psilocybin extract to UW-Madison in order for UW-Madison to conduct research and formulation work (the “Delivery and Use“), Revive’s business, products and future of Revive’s business, Mycrodose’s business, products and future of Mycrodose’s business and the Company’s business, products and future of the Company’s business. Although the Company believes that the expectations reflected in the forward-looking information are reasonable, there can be no assurance that such expectations will prove to be correct. Readers are cautioned not to place undue reliance on forward-looking information. Such forward-looking statements are subject to risks and uncertainties that may cause actual results, performance and developments to differ materially from those contemplated by these statements depending on, among other things, the risks that the Purchase Order may not be completed as contemplated, or at all, the risks that the Exportation may not be completed as contemplated, or at all, risks that the Delivery and Use may not be completed as contemplated, or at all, risks that Revive’s products and plan will vary from those stated in this news release and Revive may not be able to carry out its business plans as expected, risks that Mycrodose’s products and plan will vary from those stated in this news release and Mycrodose may not be able to carry out its business plans as expected and risks that the Company’s products and plan will vary from those stated in this news release and the Company may not be able to carry out its business plans as expected.  Except as required by law, the Company expressly disclaims any obligation and does not intend to update any forward-looking statements or forward-looking information in this news release. Although the Company believes that the expectations reflected in the forward-looking information are reasonable, there can be no assurance that such expectations will prove to be correct. The statements in this news release are made as of the date of this release.

The CSE has not reviewed, approved or disapproved the content of this press release.

SOURCE HAVN Life Sciences Inc.

For further information: Investor Relations: ir@havnlife.com, Media: savi@emergence-creative.com